BEAM vs EDIT
BEAM and EDIT side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BEAMBeam Therapeutics Inc. | EDITEDITAS MEDICINE, INC. |
|---|---|---|
| Market cap | $2.73B | $402.38M |
| P/B | 2.87 | — |
| P/S | 19.9x | 9.9x |
| Revenue | $146.64M(TTM) | — |
| Revenue growth (YoY) | 120.0% | 25.4% |
| Net income | -$108.35M(TTM) | — |
| Earnings growth (YoY) | 78.8% | 32.5% |
| EPS, diluted | $-0.88(TTM) | — |
| EBIT margin | -274.6% | -394.9% |
| ROE | -8.4% | -152.0% |
| ROIC | -45.7% | — |
| 1y total return | +10.7% | -14.7% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: BEAM vs EDIT
| Metric | BEAM | EDIT |
|---|---|---|
| End value | $14.0K | $927 |
| Total return | +40.4% | -90.7% |
| CAGR | +5.2% | -29.7% |
| Volatility | 79.5% | 92.2% |
| Sharpe | 0.40 | 0.01 |
| Sortino | 0.62 | 0.01 |
| Max drawdown | -89.1% | -98.9% |
Based on 1695 common trading days, 2020-02-06 → 2026-11-03 · risk-free 4.21% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)